Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-8527 Alone and with FTC/TDF in Healthy Participants
NCT06816043Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mk-8527 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to Last quantifiable sample and 4 more. Started Feb 2025; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06816043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816043.